Enzalutamide 915087-33-1

99% up by HPLC, PMDA, DMF

Product categories

New Products

Product Details

Product Information

Product name	Enzalutamide; MDV-3100
CAS No.	915087-33-1
Molecular Formula	C21H16F4N4O2S
Molecular Weight	464.443
Quality Standard	99.5% up by HPLC, EP/USP
Appearance	White or off-white powder

COA

ITEMS	SPECIFICATION	RESULTS
Appearance	White to off-white powder	White powder
Loss on drying	≤ 0.5%	0.04%
Residue on ignition	≤ 0.2%	0.12%
Related substance	Single impurity ≤ 0.1%	0.08%
Related substance	Total impurity ≤ 0.5%	0.21%
Purity	≥99.5%	99.79%
Residual solvent	Methanol ≤ 3000ppm	Not detected
	Ethanol ≤ 5000ppm	Not detected
	Isopropanol ≤ 5000ppm	Not detected
	n-heptane ≤ 5000ppm	180ppm
	Isopropyl acetate ≤ 5000ppm	22ppm
Conclusion	It conform to the above specification.

Usage

The function of enzalutamide:

Enzalutamide, as an androgen receptor inhibitor, is primarily used in the treatment of prostate cancer. Specifically, it is suitable for the treatment of adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT), are asymptomatic or have minimal symptoms, and have not received chemotherapy. Enzalutamide is able to inhibit the proliferation of prostate cancer cells and induce their death, thus controlling the progression of the disease.

*Products under the patent are only for R&D use